| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
1995-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_318417f1d67d9adbc26141961fc3e951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efe5a12d5a3c0364d1388deebb66c9ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af73091e27d7e246b0448983c85b26ea |
| publicationDate |
2003-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2190485-C |
| titleOfInvention |
Lacrimal gland specific emulsions for topical application to ocular tissue |
| abstract |
A pharmaceutical composition is disclosed in the form of a nonirrtating emul sion which includes at least one cyclosporin in admixtur e with a higher fatty acid glyceride and polysorbate 80. More particularly, th e cyclosporin may be cyclosporing A and the higher fatty acid glyceride may be castor oil. Composition has been found to be of a high comf ort level and low irritation potential suitable for deli very of medications to sensitive areas such as ocular tissues with enhanced absor ption in the lacrimal gland. In addition, the compositio n has stability for up to nine months without crystallization of cyclosporin.</SDO AB> |
| priorityDate |
1994-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |